It's time to move beyond "psychedelics" and begin the precision design of mood, cognition, and perception. Congrats MDL Team 👏👏
We're thrilled to announce that Mindstate Design Labs has received both FDA & EMA approval to begin human trials in the development of our neurotech platform for designing altered states. It’s time to move beyond “psychedelics” and begin the precision design of mood, cognition, and perception. Our Osmanthus platform is driven by direct human experience. It represents the scaling, quantification, and systematization of the Shulgin tradition of direct experimentation. - We’ve scaled with 70,000 human reports made possible by Shulgin’s chemistry and the psychonauts who followed in his footsteps & detailed their experiences. - We’ve quantified the latent space of subjective experience with the semantic dimensions of LLMs. - We’ve systematized the linkage between psychoactivity and biochemistry with thousands of assays of psychedelics against the sites in the brain to which they bind. The psychedelics were the tools, not the end game. They were for psychiatry what the microscope was for biology and what the telescope was for astronomy. We’ve used the tools to map the biological basis of the varieties of psychedelic effects, and we’re now moving into human trials to use those tools to design both existing and novel altered states. Our first line of psychotropic effects is built on the single base formula of the Shulgin psychedelic 5-MeO-MiPT, commonly called moxy – a “psychedelic tofu”. At normalized clinical doses there are some basic psychedelic effects but no mystical experiences or entities or blissful formless voids or immersive memory replays. 5-MeO-MiPT is a blank canvas on which to paint infinite possibilities. We take a combination approach where we break apart the serotonergic action with 5-MeO-MiPT and recombine it, one by one, with a collection of other compounds that carry pharmacologies we’ve identified as modulating one or more of the 600+ psychedelic effects we’ve catalogued. We don’t need to eliminate the psychoactive effects of psychedelics. We need the ability to choose the effects that are helpful – to transform these largely effective but unpredictable messes of psychoactive effects into a series of precision-targeted psychoactive profiles. We need to go beyond psychedelics and into mindstate design. https://lnkd.in/eYb9m9yB